GenesisCare UK

At GenesisCare, our expert teams are dedicated to delivering personalised cancer care that results in the best possible outcome for our patients. At this special time of year, we celebrate the hope and resilience of everyone touched by cancer and send warm wishes for a joyful, relaxing festive season. 🎄✨

This year our new, state-of-the-art specialist cancer care centre in Surrey, treated its first Theranostics patient🙌 Back in 2019 we were the UK’s first to treat with 177Lutetium PSMA therapy, and we're pleased to expand this cutting-edge approach - which combines diagnostics and radionuclide therapy, to Surrey and surrounding areas, offering hope for patients with advanced prostate cancer. 👉https://nuvi.me/yqbhcn #GenesisCareUK

🎉 This August, we celebrated treating 1,500 patients with the groundbreaking MRIdian technology. This fantastic milestone was achieved by our expert MRIdian teams at our centres in Oxford and Cromwell Hospital London, and our partners at University of Oxford. We remain committed to making advanced, life-changing technology available to those who need it most and look forward to celebrating more milestones in 2025. Learn more about the MRIdian here👉🏽https://nuvi.me/brraz0

GenesisCare UK, the UK’s leading private cancer care provider, is pleased to announce that it has successfully completed the refinancing transaction which replaces its current debt arrangements and provides for committed growth financing and working capital lines, which create the foundation for GenesisCare’s continued growth in the United Kingdom. The transaction, which provides GenesisCare UK with the option of drawing on funds of up to £140m, follows a successful restructuring of the global GenesisCare Group, which concluded in February 2024. The new lending facilities will be provided by Pemberton Asset Management, one of Europe’s leading private credit managers and Barclays. Justin Hely, GenesisCare’s CEO in the UK and Europe, said: “We are delighted to have completed our refinancing, which reinforces the confidence we and our partners have in the GenesisCare business and our growth strategy. Our focus remains on expanding our network of world class cancer care centres and delivering the highest possible standards of care to patients with a suspected or confirmed cancer diagnosis.” Richard Meehan, Managing Director – Origination, at Pemberton: “We are delighted to be partnering with GenesisCare UK, who are at the forefront of cancer treatment in the UK. The Group’s use of advanced treatment methods and well invested facilities enable their clinicians to deliver the highest standard of care for patients. We look forward to supporting Justin and his team in realising their growth aspirations over the coming years” Steve Fergus, Head of Healthcare at Barclays Corporate Banking, said: “We are pleased to be supporting the team at GenesisCare UK with this refinancing, and look forward to helping enable their continued success in the years ahead. This new relationship further underlines our ongoing commitment to invest for growth within this important sector.” GenesisCare was advised by Houlihan Lokey and White & Case LLP, with diligence completed by EY and Candesic. For more information about GenesisCare UK and its comprehensive cancer care services, please visit https://nuvi.me/vokeop

In 2024 we were the first UK healthcare provider to offer Optune Gio® as standard of care for eligible patients for newly diagnosed WHO Grade 4 Glioma patients. A medical device that delivers alternating electric fields, delivered at a unique frequency that allows it to selectively disrupt Grade 4 Glioma cell division 👉 https://bit.ly/3P1GQIU #GenesisCareUK #Designingbettercare

In 2024 we joined @Novartis and @MPN Voice to launch an immersive art installation outside GenesisCare in Bristol, raising awareness of the symptoms of rare blood cancers, myeloproliferative neoplasms (MPNs), to encourage people to seek help when needed ✨🎨👉 https://nuvi.me/maebja #GenesisCareUK

2024 saw the launch of our 'Second Chance' campaign, raising awareness of where secondary breast cancer might strike, and the advanced treatment options now available 💚 Find out More https://nuvi.me/wviexd #SecondChance #GenesisCareUK

This year we've continued to enhance our treatment pathways, so patients can be referred and begin treatment within days - getting the treatment they need when they need it the most. These include: 🏥 MRI-guided SABR for pancreatic cancer within 7-10 working days 🧘 Spine SABR within 7 days from referral 🧠 SRS for brain tumours within 1 week of treatment decision These streamlined pathways connect patients with expert cancer specialists and advanced treatments without delay, to ensure they achieve the best possible life outcomes. Discover more here 👉🏽https://nuvi.me/cd5ldi #designingbettercare #oncology #genesiscareuk #rapidaccess #SABR #SRS #rapidaccesspathways

Knowing the impact treatment-induced menopause can have, in 2024 #GenesisCareUK offered our patients tailored menopause support through our charity partner Penny Brohn UK. Learn more about the support we provide 👉 https://nuvi.me/25q6gl #Designingbettercare

In June, we were delighted to team up with former rugby union player, Ugo Monye, to launch our 'Know Your Roots' #prostatecancer awareness campaign. Ugo, who lost his father to prostate cancer in 2021, met with GenesisCare UK patient Andrew to discuss how encouraging men to know and share their family medical history can help save lives and improve outcomes. Learn more here 👉🏿https://nuvi.me/311sdx #knowyourroots #prostatecancerawareness #genesiscareuk